Norden Group’s Bicara Therapeutics BCAX Stock Holding History

Norden Group’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-8,911	Closed	-$265K	–	756
2026 Q2	$265K	Buy	+8,911	New	+$199K	0.02%	565

Other funds holding BCAX

RTM

Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Private Trust Company Cleveland, Ohio $1.27B AUM 20.99% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Norden Group's BCAX Position: Q3 2026 in Review

Norden Group sold out of Bicara Therapeutics (BCAX) in Q3 2026, closing a stake of 8,911 shares — an estimated $265K sold.

Norden Group first reported a position in BCAX in Q2 2026 and held it in 1 quarter. The position peaked at $265K in Q2 2026. 9 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

Norden Group reported no remaining Bicara Therapeutics position as of Q3 2026 after selling out during the quarter.
Norden Group sold 8,911 Bicara Therapeutics shares in Q3 2026, an estimated $265K.
Norden Group first reported a position in Bicara Therapeutics in Q2 2026 and held it in 1 quarter.
Norden Group's Bicara Therapeutics position peaked at $265K in Q2 2026.
9 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on Norden Group's 13F filing for Q3 2026, filed 20 Oct 2026.